Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1960 1
1962 1
1963 1
1964 1
1965 1
1967 3
1968 3
1969 4
1970 2
1971 3
1972 1
1973 4
1974 1
1975 6
1976 6
1977 14
1978 8
1979 7
1980 14
1981 8
1982 14
1983 17
1984 7
1985 10
1986 10
1987 8
1988 12
1989 4
1990 13
1991 13
1992 12
1993 17
1994 14
1995 23
1996 11
1997 20
1998 11
1999 11
2000 11
2001 11
2002 11
2003 10
2004 30
2005 42
2006 15
2007 5
2008 7
2009 12
2010 5
2011 11
2012 11
2013 3
2014 4
2015 9
2016 9
2017 12
2018 18
2019 13
2020 11
2021 9
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

570 results
Results by year
Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. Among authors: mcfadden e. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. Cameron D, et al. Among authors: mcfadden e. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Lancet. 2017. PMID: 28215665 Free PMC article. Clinical Trial.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: mcfadden e. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando K, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Jüni P, Mehran R. Valgimigli M, et al. Among authors: mcfadden ep. BMJ. 2021 Jun 16;373:n1332. doi: 10.1136/bmj.n1332. BMJ. 2021. PMID: 34135011 Free PMC article.
Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial.
Bretthauer M, Kaminski MF, Løberg M, Zauber AG, Regula J, Kuipers EJ, Hernán MA, McFadden E, Sunde A, Kalager M, Dekker E, Lansdorp-Vogelaar I, Garborg K, Rupinski M, Spaander MC, Bugajski M, Høie O, Stefansson T, Hoff G, Adami HO; Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group. Bretthauer M, et al. Among authors: mcfadden e. JAMA Intern Med. 2016 Jul 1;176(7):894-902. doi: 10.1001/jamainternmed.2016.0960. JAMA Intern Med. 2016. PMID: 27214731 Free PMC article. Clinical Trial.
Asthma.
McFadden ER Jr, Gilbert IA. McFadden ER Jr, et al. N Engl J Med. 1992 Dec 31;327(27):1928-37. doi: 10.1056/NEJM199212313272708. N Engl J Med. 1992. PMID: 1454088 Review.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators. Vranckx P, et al. Among authors: mcfadden ep. Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27. Lancet. 2018. PMID: 30166073 Clinical Trial.
Clinical end points in coronary stent trials: a case for standardized definitions.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Cutlip DE, et al. Among authors: mcfadden e. Circulation. 2007 May 1;115(17):2344-51. doi: 10.1161/CIRCULATIONAHA.106.685313. Circulation. 2007. PMID: 17470709
Exercise-induced asthma.
McFadden ER Jr, Gilbert IA. McFadden ER Jr, et al. N Engl J Med. 1994 May 12;330(19):1362-7. doi: 10.1056/NEJM199405123301907. N Engl J Med. 1994. PMID: 8152449 Review. No abstract available.
[Silent ischemia].
Bauters C, Quandalle P, Lablanche JM, McFadden E, Bertrand M. Bauters C, et al. Among authors: mcfadden e. Rev Med Interne. 1994 Jan;15(1):37-42. doi: 10.1016/s0248-8663(05)82128-9. Rev Med Interne. 1994. PMID: 8052752 Review. French.
570 results